| Obesity
Qsymia vs Foundayo
Side-by-side clinical, coverage, and cost comparison for obesity.Deep comparison between: Qsymia vs Foundayo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFoundayo has a higher rate of injection site reactions vs Qsymia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Foundayo but not Qsymia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qsymia
Foundayo
At A Glance
Oral
Once daily
Sympathomimetic amine anorectic combination
Oral
Daily
GLP-1 receptor agonist
Indications
- Obesity
- Obesity
Dosing
Obesity Start 3.75 mg/23 mg orally once daily in the morning for 14 days, then increase to 7.5 mg/46 mg once daily; may escalate to 11.25 mg/69 mg then 15 mg/92 mg based on weight loss response; maximum dose 7.5 mg/46 mg in moderate or severe renal impairment or moderate hepatic impairment; avoid in severe hepatic impairment and end-stage renal disease on dialysis.
Obesity Start at 0.8 mg orally once daily; escalate to 2.5 mg, then 5.5 mg, then optionally to 9 mg, 14.5 mg, or 17.2 mg (maximum) once daily, increasing at intervals of at least 30 days based on tolerability; take with or without food; swallow tablets whole.
Contraindications
- Pregnancy
- Glaucoma
- Hyperthyroidism
- Concomitant use or within 14 days of stopping a monoamine oxidase inhibitor (MAOI)
- Known hypersensitivity to phentermine, topiramate, or any excipient in QSYMIA, or idiosyncrasy to sympathomimetic amines
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- Known serious hypersensitivity to orforglipron or any excipient in FOUNDAYO
Adverse Reactions
Most common (>=5%) Paraesthesia, dizziness, dysgeusia, insomnia, constipation, dry mouth
Serious Embryo-fetal toxicity, suicidal behavior and ideation, acute angle-closure glaucoma, mood and sleep disorders, cognitive impairment, metabolic acidosis, decreased renal function, seizure with abrupt withdrawal, kidney stones, oligohydrosis and hyperthermia, hypokalemia, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema
Postmarketing Suicidal ideation, suicidal behavior, acute angle closure glaucoma, increased intraocular pressure, urticaria, elevation of blood pressure, ischemic events, euphoria, psychosis, tremor, anaphylaxis, angioedema, bullous skin reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), pancreatitis, hepatic failure, hyperammonemia with or without encephalopathy, maculopathy
Most common (>=5%) Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, hair loss
Serious Thyroid C-cell tumors, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure sometimes requiring hemodialysis
Pharmacology
Phentermine, a sympathomimetic amine, reduces appetite via hypothalamic catecholamine release; topiramate enhances satiety and suppresses appetite through GABA augmentation, voltage-gated ion channel modulation, AMPA/kainate glutamate receptor inhibition, and carbonic anhydrase inhibition, though the precise mechanism of action for weight reduction is not fully established for either component.
Orforglipron is a small-molecule GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor, reducing appetite and caloric intake by activating GLP-1 receptors in brain regions that regulate appetite and food intake, and also delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qsymia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (6/12)
Foundayo
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Qsymia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Foundayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Qsymia
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Foundayo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qsymia.
$149/momo
Foundayo Self-Pay Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QsymiaView full Qsymia profile
FoundayoView full Foundayo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.